Published in Immunol Invest on June 11, 2012
Progress Toward a Human Vaccine Against Coccidioidomycosis. Curr Fungal Infect Rep (2012) 0.84
Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins. J Fungi (Basel) (2016) 0.79
Fungal vaccines and immunotherapeutics. Cold Spring Harb Perspect Med (2014) 0.77
Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection. PLoS One (2015) 0.77
Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. Vaccine (2014) 0.76
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Coccidioidomycosis. Clin Infect Dis (2005) 3.88
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
Caspofungin. Clin Infect Dis (2003) 3.03
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med (2015) 2.62
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54
Coccidioidomycosis. Infect Dis Clin North Am (2003) 2.13
Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One (2013) 1.79
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother (2006) 1.76
Antifungal drug resistance. Clin Infect Dis (2003) 1.65
A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol (2004) 1.54
Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again? J Med Microbiol (2011) 1.52
Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol (2009) 1.49
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis (2003) 1.44
Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology (2002) 1.43
Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36
Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis (2003) 1.33
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2002) 1.22
The relationship between surgical factors and margin status after breast-conservation surgery for early stage breast cancer. Am J Surg (2008) 1.19
Development of a murine model of cerebral aspergillosis. J Infect Dis (2002) 1.19
Expert opinion: what to do when there is Coccidioides exposure in a laboratory. Clin Infect Dis (2009) 1.13
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol (2006) 1.06
Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia (2007) 1.05
Telepathology for routine light microscopic and frozen section diagnosis. Am J Clin Pathol (2002) 1.02
New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol (2010) 1.02
Animal models: an important tool in mycology. Med Mycol (2007) 1.01
Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med (2003) 1.00
Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun (2004) 1.00
Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J Infect Dis (2002) 1.00
Developing a vaccine against aspergillosis. Med Mycol (2010) 0.99
Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother (2008) 0.98
Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrob Agents Chemother (2004) 0.98
Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis (2008) 0.98
Herpesviruses in endodontic pathoses: association of Epstein-Barr virus with irreversible pulpitis and apical periodontitis. J Endod (2008) 0.97
Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob Agents Chemother (2012) 0.97
Metallic taste from electrical and chemical stimulation. Chem Senses (2005) 0.97
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis (2007) 0.96
Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother (2006) 0.96
Technical factors, surgeon case volume and positive margin rates after breast conservation surgery for early-stage breast cancer. Can J Surg (2010) 0.96
Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother (2004) 0.94
Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother (2006) 0.93
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med Mycol (2011) 0.92
Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother (2012) 0.92
Interferon- gamma as an antifungal. J Infect Dis (2006) 0.91
Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis (2003) 0.91
Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother (2005) 0.90
Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J Infect Dis (2006) 0.90
Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine (2009) 0.89
Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 0.89
Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model. J Antimicrob Chemother (2002) 0.89
Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine (2011) 0.88
Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother (2007) 0.88
Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev (2011) 0.87
Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother (2003) 0.87
Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis. Infect Immun (2007) 0.87
Demonstration of a novel technique to quantitatively assess inflammatory mediators and cells in rat knee joints. J Inflamm (Lond) (2007) 0.86
Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol (2010) 0.86
Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun (2004) 0.86
A murine model of coccidioidal meningitis. J Infect Dis (2003) 0.86
Who let the dogs out? Infection control did: utility of dogs in health care settings and infection control aspects. Am J Infect Control (2006) 0.86
Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol (2012) 0.86
Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease. Mycopathologia (2014) 0.85
Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D. Infect Immun (2006) 0.85
Genomic DNA microarray comparison of gene expression patterns in Paracoccidioides brasiliensis mycelia and yeasts in vitro. Microbiology (2009) 0.84